Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
Phase 2 Recruiting
30 enrolled
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
Phase 1 Recruiting
60 enrolled
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/2 Recruiting
116 enrolled
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Phase 1 Recruiting
120 enrolled
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Phase 2 Recruiting
60 enrolled
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Phase 1/2 Recruiting
63 enrolled
RADAR
Phase 3 Recruiting
1,042 enrolled
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
Phase 2 Recruiting
52 enrolled
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
Phase 2 Recruiting
130 enrolled
REaCT-OGF
Phase 4 Recruiting
242 enrolled
Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant
Phase 1/2 Recruiting
25 enrolled
Venetoclax to Augment Epigenetic Modification and Chemotherapy
Phase 1 Recruiting
40 enrolled
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
Phase 1 Recruiting
30 enrolled
HSCT
Phase 2 Recruiting
100 enrolled
hSTAR GBM
Phase 2 Recruiting
16 enrolled
RAFA
Phase 2 Recruiting
70 enrolled
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Phase 1/2 Recruiting
36 enrolled
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 2 Recruiting
270 enrolled
G-CSF After Chemo-radiation in Patients With Glioblastoma
Phase 2 Recruiting
60 enrolled
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
Phase 2 Recruiting
135 enrolled
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
Phase 3 Recruiting
3,300 enrolled